Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 4 |
List of Tables | 5 | 1 |
List of Figures | 5 | 1 |
Taiho Pharmaceutical Co., Ltd. Snapshot | 6 | 1 |
Taiho Pharmaceutical Co., Ltd. Overview | 6 | 1 |
Key Facts | 6 | 1 |
Taiho Pharmaceutical Co., Ltd. Research and Development Overview | 7 | 4 |
Key Therapeutic Areas | 7 | 4 |
Taiho Pharmaceutical Co., Ltd. Pipeline Review | 11 | 7 |
Pipeline Products by Stage of Development | 11 | 1 |
Pipeline Products Monotherapy | 12 | 1 |
Pipeline Products Combination Treatment Modalities | 13 | 1 |
Pipeline Products Partnered Products | 14 | 1 |
Partnered Products/Combination Treatment Modalities | 15 | 1 |
Pipeline Products Out-Licensed Products | 16 | 1 |
Out-Licensed Products/Combination Treatment Modalities | 17 | 1 |
Taiho Pharmaceutical Co., Ltd. Pipeline Products Glance | 18 | 6 |
Taiho Pharmaceutical Co., Ltd. Late Stage Pipeline Products | 18 | 1 |
Pre-Registration Products/Combination Treatment Modalities | 18 | 1 |
Phase III Products/Combination Treatment Modalities | 19 | 1 |
Taiho Pharmaceutical Co., Ltd. Clinical Stage Pipeline Products | 20 | 1 |
Phase II Products/Combination Treatment Modalities | 20 | 1 |
Phase I Products/Combination Treatment Modalities | 21 | 1 |
Taiho Pharmaceutical Co., Ltd. Early Stage Pipeline Products | 22 | 1 |
IND/CTA Filed Products/Combination Treatment Modalities | 22 | 1 |
Preclinical Products/Combination Treatment Modalities | 23 | 1 |
Taiho Pharmaceutical Co., Ltd. Drug Profiles | 24 | 32 |
(calcium folinate + gimeracil + oteracil + tegafur) Drug Profile | 24 | 1 |
(gimeracil + oteracil + tegafur) Drug Profile | 25 | 5 |
(tipiracil hydrochloride + trifluridine) Drug Profile | 30 | 5 |
bilastine Drug Profile | 35 | 2 |
netupitant Drug Profile | 37 | 1 |
TAS-114 Drug Profile | 38 | 1 |
TAS-115 Drug Profile | 39 | 1 |
TAS-116 Drug Profile | 40 | 1 |
TAS-117 Drug Profile | 41 | 1 |
TAS-119 Drug Profile | 42 | 1 |
TAS-120 Drug Profile | 43 | 1 |
TAS-121 Drug Profile | 44 | 1 |
TAS-205 Drug Profile | 45 | 1 |
TAS-303 Drug Profile | 46 | 1 |
TAS-3681 Drug Profile | 47 | 1 |
TAS-5567 Drug Profile | 48 | 1 |
trabectedin Drug Profile | 49 | 7 |
Taiho Pharmaceutical Co., Ltd. Pipeline Analysis | 56 | 6 |
Taiho Pharmaceutical Co., Ltd. Pipeline Products by Target | 56 | 2 |
Taiho Pharmaceutical Co., Ltd. Pipeline Products by Route of Administration | 58 | 1 |
Taiho Pharmaceutical Co., Ltd. Pipeline Products by Molecule Type | 59 | 1 |
Taiho Pharmaceutical Co., Ltd. Pipeline Products by Mechanism of Action | 60 | 2 |
Taiho Pharmaceutical Co., Ltd. Dormant Projects | 62 | 1 |
Taiho Pharmaceutical Co., Ltd. Discontinued Pipeline Products | 63 | 2 |
Discontinued Pipeline Product Profiles | 64 | 1 |
(gimeracil + oteracil + tegafur) | 64 | 1 |
(tipiracil hydrochloride + trifluridine) | 64 | 1 |
orantinib | 64 | 1 |
suplatast tosilate | 64 | 1 |
Taiho Pharmaceutical Co., Ltd. Company Statement | 65 | 1 |
Taiho Pharmaceutical Co., Ltd. Locations And Subsidiaries | 66 | 1 |
Head Office | 66 | 1 |
Other Locations &Subsidiaries | 66 | 1 |
Appendix | 67 | 2 |
Methodology | 67 | 1 |
Coverage | 67 | 1 |
Secondary Research | 67 | 1 |
Primary Research | 67 | 1 |
Expert Panel Validation | 67 | 1 |
Contact Us | 67 | 1 |
Disclaimer | 68 | 1 |